PPTDF Stock Chart & Stats
$7.20
$0.00(0.00%)
At close: 4:00 PM EDT
$7.20
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.29 - $13.24
Previous CloseN/A
Volume1.00
Average Volume (3M)603.00
Market Cap
$866.03M
Enterprise Value$128.95B
Total Cash (Recent Filing)$23.60B
Total Debt (Recent Filing)$15.69B
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 11, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.11
Shares Outstanding130,010,400
10 Day Avg. Volume1,419
30 Day Avg. Volume603
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market Cap148.89
Enterprise Value/Revenue6.71
Enterprise Value/Gross Profit15.49
Enterprise Value/Ebitda-47.86
Forecast
1Y Price Target
$14.45Price Target Upside100.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.33
Revenue Forecast (FY)$231.71M
Bulls Say, Bears Say
Bulls Say
Proprietary Peptide PlatformThe proprietary PDPS platform provides a differentiated foundation for discovering and optimizing peptide-based medicines. Its use across partnered and internal programs can support repeat collaborations, broaden the pipeline, and create opportunities for milestone and royalty income over multiple years.
Strong Revenue ReboundThe sharp TTM revenue rebound indicates renewed commercial activity and improving contribution from the company’s programs or partnerships. If this growth is sustained, it can increase operating leverage, support research investment, and improve the path toward restoring profitability.
Manageable LeverageModerate leverage and a sizable equity base provide financial flexibility while PeptiDream works to improve earnings and cash generation. This balance-sheet position may reduce near-term pressure from debt obligations and preserve capacity to fund development and partnership activities.
Bears Say
Persistent Operating LossesOngoing operating and net losses weaken the durability of the current revenue rebound and reduce internally generated funding for research. Continued losses could require tighter spending or external financing, while also making future earnings dependent on a successful profitability recovery.
Negative Cash GenerationNegative operating and free cash flow indicate that reported business activity is not currently translating into sufficient cash generation. Sustained cash burn can constrain investment in the pipeline and increase funding risk unless profitability and working-capital performance improve.
Volatile Earnings ProfileThe sharp shift from very high profitability to losses demonstrates that earnings can be uneven across development and partnership cycles. This volatility makes future results less predictable and complicates planning for research investment, staffing, and cash requirements.
Peptidream News
PPTDF FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was $5.29 and its highest was $13.24 in the past 12 months.
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is $866.03M.
When is Peptidream Inc.’s upcoming earnings report date?
Peptidream Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 35 days.
How were Peptidream Inc.’s earnings last quarter?
Peptidream Inc. released its earnings results on Aug 12, 2026. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.036.
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Undervalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate is -0.04.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Peptidream Inc. reported an EPS of -$0.056 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -3.045%.
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in PPTDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
PPTDF Company Deck
PPTDF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial operational and pipeline progress — notably strong clinical momentum (6 programs entering clinic in 2025, 13 total clinical programs), late-stage radiopharmaceutical programs with NDA timelines, IND acceptances and a healthy cash balance (JPY 28.6 billion). At the same time, key revenue drivers were delayed (notably the myostatin out‑licensing), R&D and headcount-driven costs are increasing (R&D +28% year-over-year; headcount +6.4%), and several high-value deals remain timing-uncertain. Overall, the company appears to be transitioning from a discovery-focused model to a discovery-and-development company with meaningful upside from pipeline advances, but near-term financial performance depends on timing of large upfront deals and execution of planned manufacturing expansions.View all PPTDF earnings summariesPPTDF Stock 12 Month Forecast
Average Price Target
$14.45
▲(100.73% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.66% Mutual Funds
― Other Institutional Investors
92.33% Public Companies and
Individual Investors